A VISIONaerie® approach
We discover, develop and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases
News HighlightsAerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial R... Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® ... Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the ...
Feb 26, 10:11 AM ET
52 - WEEK LOW/HIGH